FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Take Down. What’s Next? | Pharmacy Times

The FDA’s war on compounded GLP-1 drugs just escalated to a level that should make every telehealth platform and compounding pharmacy sit up and pay attention. After sending over 55 warning letters to online sellers last September, the agency dropped another 30 in late February 2026, targeting telehealth companies it says are making false claims about compounded versions of semaglutide and tirzepatide. And Novo Nordisk isn’t just watching from the sidelines. It’s suing.

What’s Actually Happening

The crackdown started in September 2025 when the FDA fired off more than 55 warning letters to companies selling compounded GLP-1 receptor agonists online. These aren’t small-time operations. We’re talking about telehealth platforms openly marketing compounded semaglutide and tirzepatide as alternatives to brand-name Wegovy and Zepbound.

Then on February 20, 2026, the FDA issued another 30 warning letters, signed by Matthew J. Lash, Acting Director of the Office of Compounding Quality and Compliance. The agency’s core complaints include:

• “Sameness” claims that equate compounded products with FDA-approved drugs
• Trademarked marketing that obscures who’s actually doing the compounding
• Promotional language suggesting compounded versions have the same safety and efficacy as brand-name medications
• Direct-to-consumer advertising the FDA considers misleading

The volume of regulatory correspondence has been staggering. The FDA has reportedly sent thousands of letters since September, surpassing the cumulative total of the previous decade.

The Novo Nordisk vs. Hims & Hers Saga

On February 9, 2026, Novo Nordisk sued Hims & Hers for patent infringement, alleging the telehealth giant continued to “mass compound injectable versions” of semaglutide using inauthentic API while running campaigns suggesting its products compared favorably to Wegovy. That’s a bold legal move from a pharma company that clearly felt the FDA wasn’t moving fast enough.

But here’s the twist. Just one month later, on March 9, the two companies announced they’d resolved their dispute and entered a partnership instead. Under the deal, Hims & Hers will offer Novo Nordisk’s branded semaglutide products (Ozempic and Wegovy) on its telehealth platform while pulling back on compounded GLP-1 advertising. It’s a remarkable pivot from courtroom to collaboration.

Why This Matters for the Peptide Community

The backdrop here is important. The FDA lifted the shortage designation for tirzepatide in late 2024 and semaglutide came off the shortage list as well. Under FDA rules, compounders could produce versions of these drugs during declared shortages. Once those shortages ended, the legal ground shifted dramatically.

Despite that, many telehealth platforms and online pharmacies kept selling compounded versions as if nothing had changed. The FDA’s position is clear: that’s not legal, and the marketing around it is misleading.

Safety concerns add urgency to the enforcement push. According to Healthcare Brew, the FDA flagged manufacturing issues at one compounder, GenoGenix, where three patients ended up in the emergency room after taking compounded products.

What Comes Next

The Hims-Novo deal likely sets the template. Big telehealth players will probably cut similar agreements with brand manufacturers rather than fight both lawsuits and FDA enforcement simultaneously. Smaller compounders without that face a tougher road.

STAT News reports the FDA is now looking beyond the companies themselves and at the prescribers behind the telehealth platforms. Regulators have also hinted at potential product seizures, which would represent a significant escalation from warning letters.

For consumers currently using compounded GLP-1 products, this is a moment to ask hard questions about your source. The gap between a compounded product made during a legitimate shortage and one marketed through misleading advertising after that shortage ended isn’t just a legal distinction. It’s a safety one. The FDA’s enforcement is only going to intensify from here.